Search - tctmd.com

Displaying 21 - 40 of 50

Sort: Relevancy | Date

News Daily News

Stroke Not the Only Concern in Patients With A-fib

September 07, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

September 01, 2016

News Conference News ESC 2016

Edoxaban Shows Safety, Efficacy for A-fib Patients Undergoing Cardioversion: ENSURE-AF

August 30, 2016

News Conference News ESC 2016

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Michael O'Riordan

August 28, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Warfarin Control Over Time Is Shaky Even in Those Who Are Initially Stable

August 10, 2016

News Daily News

Study Provides More Evidence That Having A-fib Ups Risk of Developing Dementia

July 19, 2016

News Daily News

Rivaroxaban podría Ayudar a Disolver Trombos Auriculares Izdos. en Pacientes con FA

June 09, 2016

News Daily News

Rivaroxaban May Help Dissolve Left Atrial Thrombus in Patients With A-fib

June 09, 2016

News Conference News EuroPCR 2016

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Yael L. Maxwell

May 17, 2016

News Daily News

Good Warfarin Management Prevents Complications in A-fib Patients, Swedish Study Contends

April 21, 2016

News Daily News

In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients

January 25, 2016

News Daily News

研究肯定了 Watchman 左心耳封堵器减少卒中的成本效益

December 14, 2015

News Daily News

Un Estudio Confirma la Rentabilidad del Dispositivo Watchman para el Cierre del AAI en el Descenso de ACV

December 14, 2015

News Daily News

Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction

December 14, 2015

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

News Daily News

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

October 26, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

October 26, 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Martin W Bergmann

October 15, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.